Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on August 21, 2023.

HWAIL PHARMACEUTICAL CO., LTD. is a Korea-based company mainly engaged in the manufacture and distribution of pharmaceutical raw materials. The Company produces aceclofenac, lornoxicam, triflusal, dicloalphenazone, gallamine triethyl iodide, acemetacin, levosulpiride, alibendol, erdostein, talniflumate, topiramate, phloroglucin, oxatomide and others used as expectorants, cough remedies, antispasmodics, analgesics, anti-inflammatories and others under the brand name EDST, TRPR, LVSP, ACCL and others. It also provides finished formulations, including injection products such as ceftazidime, cefoperazone, cefotaxime, cefaclor, cefatrizine, cefroxadine and others. The Company distributes its products within domestic market and to overseas markets.